This is a snippet of the transcript.Contact Salesto get full access.
It sounds very simple, but it means setting the rules. This was a significant project even when I was there, and I don't know if it is completed. For me, that was a big opportunity. If you can remove certain cases that clinical teams are reviewing unnecessarily, even a small increase in percentage can lead to significant cost savings. I remember benchmarking, and I might mess up the percentages, but I think we were in the low single digits for auto approvals, while industry-wide it was in the double digits, over 15%. For me, that was a big opportunity. However, it goes back to our identity. Are we a tech company or an insurance company? We wanted to build everything from scratch. The entire platform was built in-house, and part of the team that I stood up was a dedicated vertical that worked almost daily on some of the tech or product-related work. We were able to get feedback from nurses using the platform to fix bugs and make improvements. Even with auto approval, when I started, less than 1% of cases were auto-approved. I thought we should be hitting 25% by the end of the year. But because we wanted to build everything from scratch, my personal view was to bring in someone who does this well while we build internally, so we could achieve this quickly and save costs. However, because we wanted to build everything in-house, we continued to work on it. Given we are a tech company with limited resources, there were multiple projects, leading to resource constraints and delays, causing further burden. Long story short, can technology help reduce variable costs? Yes, most definitely. Is Oscar doing that well? It's a work in progress. There are many pain points that can be addressed.
This is a snippet of the transcript.Contact Salesto get full access.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2025 IP 1 Ltd. All rights reserved.
Subscribe to access hundreds of interviews and primary research